Spotlight Medical Secures €6.2M in Seed Funding to Advance AI-Driven Prognosis Tests for Precision Medicine
Spotlight Medical is at the forefront of precision medicine, utilizing advanced AI technologies to develop prognosis tests that aid in determining the best treatment strategies for patients, particularly in the field of cancer treatment.
Company Name: Spotlight Medical
Location: Paris, France
Sector: Healthcare, Artificial Intelligence
Funding Details: Raised €6.2M in Seed funding. The round was led by Kurma Partners and Heal Capital.
Purpose of Investment: To bring the company’s first AI-driven prognosis test to the clinic, a critical step towards commercialization.
Leadership: Led by CEO Sylvain Berlemont.
Product: Spotlight Medical is pioneering the development of AI-driven prognosis tests designed to enhance treatment selection. By leveraging extensive historical patient data, the company’s tests aim to personalize treatment plans, ensuring that each patient receives the most effective care tailored to their specific condition. This approach significantly improves patient outcomes and quality of life.
About Company: Spotlight Medical is at the forefront of precision medicine, utilizing advanced AI technologies to develop prognosis tests that aid in determining the best treatment strategies for patients, particularly in the field of cancer treatment. With this new funding, the company is poised to transition its innovative AI solutions from development to clinical application, marking a significant advancement in the integration of AI into healthcare diagnostics and treatment planning.
